Introduction {#S5}
============

Fatigue is one of the most common and debilitating symptoms affecting cancer patients and survivors \[[@R1]--[@R4]\]. Cancer-Related Fatigue (CRF) is defined by the National Consortium of Cancer Centers (NCCN) as a "persistent subjective sense of tiredness related to cancer or cancer treatment that interferes with usual functioning" \[[@R5]\]. It is a major cause of non-adherence to cancer treatment regimens \[[@R6]\], and higher fatigue may predict worse survival \[[@R7]\]. CRF is associated with decreased psychological, occupational, and social functioning \[[@R8]--[@R10]\], and can persist for years after treatment \[[@R11]--[@R13]\]. The prevalence of CRF among cancer patients during treatment ranges from 25% to 99% depending on the diagnostic criteria used to determine the condition and the sample \[[@R14]\].

The etiology of CRF is multi-factorial including a wide range of potential physiologic and psychologic mechanisms. Models of the inflammatory cytokine activity in response to the cancer or the treatment have been amongst the most extensively studied theorized mechanisms \[[@R15]--[@R17]\]. Additionally, neuroendocrine-based regulatory models have been implicated in many facets of fatigue \[[@R18]--[@R21]\]. Furthermore, co-morbidities associated with CRF are likely to contribute to its development including anemia, cachexia, depression and sleep disorders \[[@R22]\]. Additionally, different treatment modalities are associated with different rates of CRF \[[@R23]\]. Radiation Therapy \[RT\] has been shown to be particularly associated with the development of CRF \[[@R24]\]. Due to the fairly elusive underlying pathphysiology of CRF, a variety of interventions may be needed to effectively manage this condition.

Interventions have been researched to treat CRF include exercise, pharmacologic and psychosocial interventions. Numerous medications have been evaluated, although only methylphenidate has been shown to be effective. The data supporting its utility are mixed and the clinical significance of the benefit has been variable \[[@R25]\]. There are also a number of non-pharmacologic interventions that have been studied. Exercise, energy conservation as well as herbal remedies have been evaluated with mixed success \[[@R26]--[@R30]\]. At this time, there has been no treatment that improves CRF in all settings.

Evidence is limited for psychosocial interventions in the reduction of CRF during active cancer treatment \[[@R31]\]. The most effective interventions were those that included individual counseling sessions specifically focusing on fatigue. Behaviorally oriented interventions including aspects such as counseling and educating the patient about fatigue & how to self-care, activity management and coping techniques have been shown to be effective \[[@R32]\]. In addition, Cognitive Behavioral Therapy aimed at improving sleep practices has been shown to improve fatigue scores with lasting effect at follow up in one trial \[[@R33],[@R34]\]. Psychosocial interventions are promising and more research must be done to determine the optimal format for delivery of information to patients, including duration and content \[[@R31]\].

In recognizing the clinical importance of CRF, the National Cancer Institute (NCI) Physician Data Query (PDQ)® program synthesizes the best available emerging evidence coupled with expert input and provides information via the Internet to help patients and health care providers to manage this debilitating symptom \[[@R35]\]. Despite the availability of this valuable resource, no study to date has attempted to translate the NCI guidelines into practice or to evaluate the outcome in a clinical setting. This effort is critically needed to ensure knowledge generated from clinical trials can become effective strategies that improve patient care. In addition, by understanding how CRF manifests in current guideline-based management we can begin designing and testing additional interventions for specific at-risk populations to create a personalized fatigue management strategy for cancer patients. Thus, the specific aims of this study are: 1) To evaluate the progression of fatigue among a cohort of RT patients who received the NCI guideline on CRF at baseline; 2) To identify factors associated with greater fatigue at the end of RT even with the guideline-based counseling; 3) To evaluate patients' receptiveness and adherence to specific recommendations that were highlighted by the NCI guideline.

Methods {#S6}
=======

Design {#S7}
------

We conducted a prospective cohort study among patients who were receiving non-palliative RT at the Hospital of the University of Pennsylvania (Philadelphia, PA). Inclusion criteria included being at least 18 years of age, receiving non-palliative RT treatment, being at least 14 days post-ambulatory surgery, having a Karnofsky score of 60 or better, and having an ability to read and understand English. The study excluded those with chart-documented anemia (defined as most recent hemoglobin level of less than 8.5 (g/dl) or having ongoing treatment for anemia), a known brain tumor or brain metastasis (because neurocognitive changes caused by cancer or RT could impact the completion of self-reported outcomes), and chart documentation of a recent or ongoing diagnosis of a significant depressive episode. The study was approved by the University of Pennsylvania Institutional Review Board.

Procedures {#S8}
----------

Trained Research Assistants (RAs) screened patients' eligibility via Electronic Medical Record (EMR) and approached eligible patients for informed consent and enrollment at the baseline week of RT. Patient Reported Outcomes (PRO) along with self-reported social demographic information were collected at baseline and the last week of RT. RAs abstracted clinical information including cancer type, stage of disease, RT duration, number of RT fractions, number of weeks undergoing RT, RT dose, medical co-morbidities and medications from EMR.

Brief Behavioral Counseling: We aimed at designing brief behavioral counseling that can be easily integrated into RT care. Counseling was created based on content described on the NCI website (last modified, May 31, 2007) \[[@R35]\] and lasted between five and ten minutes ([Table 1](#T1){ref-type="table"}). An experienced mental health counselor and a palliative care physician trained RAs on delivering the content of NCI guidelines and on optimal ways of communicating the message to patients. The RAs performed the counseling face to face during the initial week of RT. A patient handout based on NCI fatigue PDQ® for patients was given to each participant at the end of counseling. To evaluate the effectiveness of the behavioral counseling, we designed a Likert scale questionnaire to ask the participant to rate the helpfulness of the counseling experience during the final week of the RT treatment course. Response options ranged from "Not at all" to "Very Much So". We also asked the patient to self-report use of specific activities highlighted in the guideline at this time. For specific therapies, we then asked participants to rate the helpfulness from "Not at all helpful" to "Very Helpful".

Outcomes {#S9}
--------

Brief Fatigue Inventory (BFI)-Primary outcome: The BFI consists of 9 items that measure the severity and interference of fatigue. The average of the 0--10 scores of the items yield a global index score with a higher number indicating more severe fatigue. The BFI is easy to understand, has strong internal consistency reliabilities (Cronbach's α is 0.96), correlates well with other measures of fatigue \[[@R36]\], and appears to be responsive over time \[[@R37]\] as well as to interventions \[[@R38]\].

MD Anderson Symptom and Interference Inventory (MDASI) -- secondary outcome: The MDASI is an instrument that measures common symptoms in cancer patients undergoing treatment with demonstrated reliability and validity \[[@R39],[@R40]\]. It contains 19 items that measure the severity of a variety of symptoms and their impact on daily functioning. Of the 19 items, 13 assess the severity of the following symptoms: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, memory loss, appetite loss, drowsiness, dry mouth, sadness, vomiting, and numbness/tingling. These items are graded from 0 (the symptom is "not present) to 10 (the symptom is "as bad as you can imagine"). The remaining six items measure how the symptoms impact general activity, mood, work, relations with other people, walking, and enjoyment of life. These items are also graded from 0 (the symptom "did not interfere") to 10 (the symptom "interfered completely"). The scale has two domains: symptom severity and interference. We incorporated MDASI into this research to understand the relationship between fatigue and overall symptom distress in this population.

Data analyses {#S10}
-------------

Statistical analysis was performed using STATA 10.0 for Windows (STATA Corporation, College Station, TX). Appropriate descriptive statistics including examination of proportion mean, median, and range were performed for both outcomes and relevant covariates. We then performed paired t-test for BFI and MDASI comparing before and after RT. Bivariable analyses were performed to identify any socio-demographic and clinical variables that are associated with BFI at the end of RT. We then developed multivariate regression analysis with BFI at the end of RT as the dependent variable incorporating those covariates that were significant at the 0.10 level as independent variables. Because observed differences in fatigue progression varied by the receipt of chemotherapy status, we also performed a paired t-test stratified by chemotherapy status. Further, we performed a Pearson correlation between BFI and MDASI scores to understand how fatigue relates to overall symptom severity and interference. All statistical analyses were two-sided with p\<0.05 indicating significance.

Results {#S11}
=======

Characteristics of the sample {#S12}
-----------------------------

Of the 115 eligible patients based on initial screening, 109 were approached and 100 (91.7%) agreed to participate. Among the 9 (8.2%) patients that declined to participate, 6 (5.5%) did not want to participate in a research study, 2 (1.8%) were fearful of releasing personal or health information, and 1 (0.9%) did not want to consider negative side effects of treatment. Additionally, 4 subjects withdrew consent and 3 subjects discontinued because of hospitalization prior to the behavior counseling, resulting in the final sample of 93 and a response rate of 85.3%. Of the 93 subjects enrolled ([Table 2](#T2){ref-type="table"}), 57 (61.3%) were men, 65 (69.9%) were white, 44 (48.4%) had gone to college, 40 (44%) were employed full-time at the time of the survey, and the mean age was 65 years at the time of the survey. The most prevalent tumor type was prostate (47.3%), then breast (29%), with a mix of tumors (23.7%) for the remaining study population. A large portion of the subjects (69.9%) had not received any chemotherapy in the course of their treatment, and 17.2% received concurrent chemotherapy and during the course of radiation therapy. The average cumulative radiation dose was 7200 cGy, with a range of 4500 to 8000 cGy. Enrolled subjects generally had other comorbid conditions and were on numerous medications.

Progression and risk factors for fatigue {#S13}
----------------------------------------

For the entire cohort, fatigue as measured by the BFI increased from 2.1 at the baseline to 2.9 at the end of RT, p\<0.001. However, when stratified by chemotherapy status ([Figure 1](#F1){ref-type="fig"}), fatigue showed a significant but small increase for those who received RT only (from 1.7 to 2.4, p=0.02) and was stable for those who received chemotherapy prior to RT (from 3.3 to 3.1, p=0.75). Nevertheless, fatigue increased substantially for those who received chemotherapy during RT (from 3.0 to 5.2, p = 0.05).

In bivariable analyses, only the baseline BFI score and chemotherapy status were associated with increased fatigue at the end of RT. In a model adjusting for these two variables, any 1 point of increase in BFI score at baseline was associated with a 0.6 point increase in BFI at the end of RT, 95% confidence interval (CI), 0.3--0.8, p\<0.001. Compared with those who received RT only, individuals who had concurrent chemotherapy had 2.1 points higher in BFI score, 95% CI 0.6--3.5, p = 0.006 at the end of RT.

Fatigue, overall symptom severity and interference {#S14}
--------------------------------------------------

The global symptom severity and interference measured by MDASI increased significantly during the RT course, (1.2 to 1.9 for severity, p = 0.0003) and (1.4 to 2.2 for interference, p = 0.0001), ([Figure 2](#F2){ref-type="fig"}). The fatigue item in the MDASI was also the one symptom that had the highest severity score both at baseline and end of RT and represented the most change through RT (2.1 to 3.6, p\< 0.0001). The change in BFI score was highly correlated with the change in MDASI symptom severity (0.70, p\< 0.0001) and symptom interference (0.81, p\< 0.0001).

Evaluation of behavior counseling {#S15}
---------------------------------

The recommendations for CRF by the NCI were very well received by participants: 89% of patients found the guidelines to be useful and practical, 98% thought the material was presented by the counselor at an appropriate level, 98% could easily comprehend the material, 91% viewed the handouts (based on NCI PDQ® for patients) provided by the counselor as beneficial to their understanding, and 96% believed their questions were answered satisfactorily by the counselor.

Uptake and perceived helpfulness of activities dealing with CRF {#S16}
---------------------------------------------------------------

Of the 79 available participants at the end of RT, the most common activities performed by individuals were napping during the day (74%), followed by prioritizing daily activities (73%), talking to others with cancer (71%), increasing exercise (59%), and receiving nutritional counseling (42%). While not part of NCI guidelines and not reviewed by our counselor, 33% of individuals decreased exercise and 22% took herbal or natural supplements; however, only 20% of individuals took medications.

The interventions endorsed as most helpful ("very helpful") by individuals who used them were talking with others who had cancer (29.1%), prioritizing daily activities (28.6%), nutritional counselling (28.1%), napping during the day (26.7%), and taking medications (26.7%). The majority of patients viewed increasing exercise as at least somewhat helpful (87%), while a large proportion (61.5%) of those who decreased exercise did not believe it helped CRF at all. Interestingly, the two activities that were not endorsed by NCI - decreasing exercise (61.5%) and herbal supplements (29.4%) -had the highest proportion of individuals who perceived these activities as not helpful. Among those who took a medication (N=15), all used methylphenidate and perceived some degree of benefit from taking medication.

Discussion {#S17}
==========

This study sought to translate the NCI (PDQ)® guidelines for CRF into clinical practice and to evaluate their impact on controlling CRF. We found that a brief 5--10 minute counseling session provided by individuals without formal medical or counseling background was well-received by patients. Fatigue remained fairly stable for those who did not receive concurrent chemotherapy. Higher baseline fatigue and receipt of chemotherapy were risk factors for developing worsened fatigue at the end of RT. Fatigue was the most distressful symptom reported by participants and was highly correlated with overall symptom severity and interference on daily living. Many patients performed the activities highlighted in the guidelines and perceived them as helpful. Despite this, those who had concurrent chemotherapy experienced a substantial increase in fatigue.

It is important to acknowledge several limitations prior to discussing the implication of our findings. Our study was not a trial. It was pragmatic in nature and the lack of a control arm could not provide direct causal evidence for the specific efficacy of brief behavioral counseling for CRF. Our sample size was small, which may limit the degree to which we were able to study other prognostic factors related to CRF. Furthermore, the loss to follow-up may also affect results in unknown directions. Lastly, our study was performed in an urban tertiary cancer center, which limits the generalizability of the study.

Numerous studies have demonstrated that CRF increases over the course of RT \[[@R41]--[@R47]\]. Our study found that those who did not have chemotherapy had fatigue in the "mild" range before and after RT with minimal change. It is also possible that the lack of change may be due to a "response shift," which occurs when patients become accustomed to their fatigue \[[@R48]--[@R51]\]. However, in contrast to a marked increase in fatigue by those who received concurrent chemotherapy, the lack of change cannot be entirely attributed to this phenomenon.

The finding that fatigue increased substantially (from 3 to 5.2 on BFI) in those who are receiving both RT and chemotherapy is consistent with previous studies that show that patients receiving a combination of the two therapies have higher levels of fatigue compared to those receiving a single therapy \[[@R23],[@R52],[@R53]\]. The CRF associated with each cancer subtype and its therapy may be distinct in its pathophysiology as well as appropriate treatments. For example, exercise is a common intervention recommendation for CRF, and an optimal regimen was found to involve moderate-intensity and resistance exercises. However, exercise has shown to be most beneficial only for breast and prostate cancer survivors. In contrast, exercise has not shown significant improvements in fatigue for leukemia, lymphoma and colorectal cancer survivors \[[@R27]\]. Thus interventions need to be developed and tested in the context of existing guideline-based counseling to find strategies to decrease CRF in each specific population. According to our analysis, the population of cancer patients who get concurrent radiation and chemotherapy would be a group at particularly high risk.

The vast majority of participants felt that the counseling provided helpful information in an appropriate format. NCI PDQ® is readily available and updated regularly to incorporate research evidence and expert opinions. Efforts like our study are needed to make sure that this work that can be easily incorporated into clinical care and, ultimately, affect patient care. The fact that most participants adhered to at least one of the recommended NCI interventions ([Table 3](#T3){ref-type="table"}) and perceived all of the interventions as at least "somewhat helpful" further suggests that our educational model could be effective in CRF management. Our high rate of participation indicates that cancer patients readily welcome suggestions on how to manage their CRF. Moreover, our intervention was administered by trained RAs. This raises the possibility that a doctor or specialist may not be required to provide this guidance. It is thus possible that a health care provider such as a medical assistant who becomes well-versed in the NCI guidelines may deliver the intervention. This can help circumvent the lack of resources and funding, which create barriers for patients and their families to utilize effective therapies \[[@R54]\].

To our knowledge, this is the first study to demonstrate that brief behavioral counseling based on the NCI (PDQ)® guidelines can be easily implemented in an RT setting and that it is welcomed by most cancer patients. Many patients participated in the activities recommended by the guideline and perceived them as helpful. Our study was also able to identify two high-risk groups for the development of more severe CRF: those patients who received concurrent chemotherapy and those with a higher baseline fatigue. More research is needed to develop and test innovative or tailored interventions to target these at-risk groups. With risk assessment and specific effective interventions, we can ultimately adopt a personalized fatigue management strategy for diverse populations of cancer patients.
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###### 

Interventions recommended to patients to cope with cancer-related fatigue.

  --------------------------------------------
  Try to sleep at least 8 hours each night
  Plan time to rest/take naps
  Try not to do too much
  Exercise
  Plan a work schedule that is right for you
  Let others help you at home
  Learn from others who have cancer
  Plan a radiation schedule that fits you
  Talk with your doctor or nurse
  --------------------------------------------

Developed basing from the National Cancer Institute Fatigue PDQ® patient handout

###### 

Participant characteristics (N=93).

  Demographic                                    
  --------------------------------------- ------ --------------
  **Age (Median, range)**                 65     38--85
  **Sex (N, %)**                                 
   Male                                   57     61.3
   Female                                 36     38.7
  **Race/Ethnicity (N, %)**                      
   White                                  65     69.9
   Non-white                              28     30.1
  **Education (N, %)**                           
   Graduate or professional school        24     26.4
   College or some college                44     48.4
   High school or less                    23     25.3
  **Employment (N, %)**                          
    Not Currently                         51     56.0
    Working                               40     44.0
  **Clinical**                                   
  **Stage (N, %)**                               
   I                                      42     44.2
   II                                     28     30.4
   III                                    23     24.7
  **Diagnosis (N, %)**                           
   Prostate                               44     47.3
   Breast                                 27     29.0
   Others                                 22     23.7
  **Surgery (N, %)**                             
   None                                   48     51.6
   Yes                                    45     48.4
  **Chemotherapy (N, %)**                        
   None                                   65     69.9
   Before                                 12     12.9
   Concurrent                             16     17.2
  **Hormone therapy (N, %)**                     
   None                                   63     67.7
   Yes                                    30     32.3
  **Co-morbidities (Mean, SD)**           3.0    2.4
  **Medications (Mean, SD)**              6.3    3.7
  **Radiation Therapy (Median, Range)**   7200   (4500, 8000)

###### 

Activities performed to cope with cancer-related fatigue (N=79).

                                                            Among those who performed the interventions, perceived helpfulness of each intervention                                       
  --------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------- ----------- ----------- -----------
                                                            N (%)                                                                                     N (%)       N (%)       N (%)       N (%)
  Increase Exercise                                         46 (59.0)                                                                                 6 (13.0)    19 (41.3)   13 (28.3)   8 (17.4)
  Decrease Exercise[\*](#TFN2){ref-type="table-fn"}         26 (33.3)                                                                                 16 (61.5)   3 (11.5)    4 (15.4)    3 (11.5)
  Nutritional Counseling                                    32 (41.6)                                                                                 2 (6.3)     13 (40.6)   8 (25.0)    9 (28.1)
  Prioritize Daily Activities                               56 (72.7)                                                                                 2 (3.6)     27 (48.2)   11 (19.6)   16 (28.6)
  Nap During the Day                                        58 (74.4)                                                                                 3 (5.2)     18 (31.0)   21 (36.2)   16 (27.6)
  Relaxation Techniques                                     21 (27.3)                                                                                 4 (19.1)    9 (42.9)    7 (33.3)    1 (4.76)
  Medication                                                15 (19.5)                                                                                 0 (0.0)     6 (40.0)    5 (33.3)    4 (26.7)
  Herb/Natural Supplement[\*](#TFN2){ref-type="table-fn"}   17 (22.1)                                                                                 5 (29.4)    5 (29.4)    3 (17.7)    4 (23.5)
  Talk to Others with Cancer                                55 (70.5)                                                                                 1 (1.8)     30 (54.6)   8 (14.6)    16 (29.1)

Not endorsed by National Cancer Center guideline
